Razelle Kurzrock
Distinguished in Lymphoid Hyperplasia

Dr. Razelle Kurzrock

Hematology Oncology | Hematology | Oncology
9200 W Wisconsin Ave, 
Milwaukee, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
41 Years of Experience
Distinguished in Lymphoid Hyperplasia
9200 W Wisconsin Ave, 
Milwaukee, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Razelle Kurzrock is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Kurzrock has been practicing medicine for over 41 years and is rated as a Distinguished provider by MediFind in the treatment of Lymphoid Hyperplasia. Her top areas of expertise are Castleman Disease, Multicentric Castleman Disease (MCD), Lymphoid Hyperplasia, Adult Soft Tissue Sarcoma, and Tissue Biopsy. Dr. Kurzrock is currently accepting new patients.

Her clinical research consists of co-authoring 727 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 15 articles in the study of Lymphoid Hyperplasia.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WI
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Children's Community Health
  • EPO
  • PPO
Network Health
  • HMO

Locations

9200 W Wisconsin Ave, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

UCSD Profile Related Evidence Determining Individualized Cancer Therapy (UCSD PREDICT)
UCSD Profile Related Evidence Determining Individualized Cancer Therapy (UCSD PREDICT)
Enrollment Status: Recruiting
Publish Date: October 26, 2024
A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors
A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: August 21, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies
Enrollment Status: Completed
Publish Date: November 22, 2024
Intervention Type: Biological
Study Drug: Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody
Study Phase: Phase 1
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: April 28, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
Enrollment Status: Terminated
Publish Date: May 06, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
Enrollment Status: Completed
Publish Date: September 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Multicenter, Histology-Independent Study of the Fibroblast Growth Factor Receptor (FGFR) Inhibitor Lenvatinib (E7080) in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
A Multicenter, Histology-Independent Study of the Fibroblast Growth Factor Receptor (FGFR) Inhibitor Lenvatinib (E7080) in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
Enrollment Status: Withdrawn
Publish Date: August 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Histology-Independent Study of the Cyclin Inhibitor Palbociclib in Patients With Advanced Cancer Harboring Aberrations in the Cyclin Pathway
A Histology-Independent Study of the Cyclin Inhibitor Palbociclib in Patients With Advanced Cancer Harboring Aberrations in the Cyclin Pathway
Enrollment Status: Withdrawn
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

727 Total Publications

Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review.
Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 17, 2025
Similar Doctors
Advanced in Lymphoid Hyperplasia
Dr. Michael E. Keefe
Hematology Oncology | Hematology | Oncology
Advanced in Lymphoid Hyperplasia
Dr. Michael E. Keefe
Hematology Oncology | Hematology | Oncology

Columbia St Marys Hospital Milwaukee Inc

2350 N Lake Dr, 
Milwaukee, WI 
 (7.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Keefe is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Keefe is rated as a Distinguished provider by MediFind in the treatment of Lymphoid Hyperplasia. His top areas of expertise are Thrombocytopenia, Unicentric Castleman Disease (UCD), Multicentric Castleman Disease (MCD), and Castleman Disease. Dr. Keefe is currently accepting new patients.

Experienced in Lymphoid Hyperplasia
Dr. Abdel I. Alqwasmi
Hematology Oncology | Hematology | Oncology
Experienced in Lymphoid Hyperplasia
Dr. Abdel I. Alqwasmi
Hematology Oncology | Hematology | Oncology

The Medical College Of Wisconsin Inc

W180n8085 Town Hall Rd, Suite 301, 
Menomonee Falls, WI 
 (10.2 miles away)
262-257-3200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Abdel Alqwasmi is a Hematologist Oncology specialist and a Hematologist in Menomonee Falls, Wisconsin. Dr. Alqwasmi is rated as a Distinguished provider by MediFind in the treatment of Lymphoid Hyperplasia. His top areas of expertise are Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Small Cell Lung Cancer (SCLC). Dr. Alqwasmi is currently accepting new patients.

Experienced in Lymphoid Hyperplasia
Dr. H M. Matthews
Hematology Oncology | Hematology | Oncology
Experienced in Lymphoid Hyperplasia
Dr. H M. Matthews
Hematology Oncology | Hematology | Oncology
1621 N Taylor Dr, Suite 100, 
Sheboygan, WI 
 (51.7 miles away)
920-458-7433
Languages Spoken:
English
See accepted insurances
Accepting New Patients

H Matthews is a Hematologist Oncology specialist and a Hematologist in Sheboygan, Wisconsin. Dr. Matthews is rated as an Advanced provider by MediFind in the treatment of Lymphoid Hyperplasia. His top areas of expertise are Myelodysplastic Syndrome (MDS), Childhood Iron Deficiency Anemia, Intraductal Papilloma, and Small Cell Lung Cancer (SCLC). Dr. Matthews is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kurzrock's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 25 Advanced Conditions
View All 59 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile